Telavancin

Summary

Telavancin (CHEMBL507870) is an approved protein antibacterial drug (ATC J01XA03); indicated across 7 conditions including bacterial infectious disease with sepsis and bacterial pneumonia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: J01XA03
• Indications: 7 conditions
• Clinical trials: 15
• Chemistry: 1755.6 Da · C80H106Cl2N11O27P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL507870
Name	Telavancin
Type	Protein
Max phase	4
FDA approved	yes
PubChem CID	3081362
ChEBI	CHEBI:71229
ATC	J01XA03
Molecular formula	C80H106Cl2N11O27P
Molecular weight	1755.6
InChIKey	ONUMZHGUFYIKPM-MXNFEBESSA-N

SMILES: CCCCCCCCCCNCCN[C@]1(C[C@@H](O[C@H]([C@H]1O)C)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C(=C(C=C9[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)O)CNCP(=O)(O)O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)C

IUPAC name: (1S,2R,18R,19R,22S,25R,28R,40S)-22-(2-amino-2-oxoethyl)-5,15-dichloro-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5S,6S)-4-[2-(decylamino)ethylamino]-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,18,32,35,37-pentahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-36-[(phosphonomethylamino)methyl]-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid

ChEBI definition: A glycopeptide that is vancomycin substituted at position N-3’’ by a 2-(decylamino)ethyl group and at position C-29 by a (phosphonomethyl)aminomethyl group. Used as its hydrochloride salt for treatment of adults with complicated skin and skin structure infections caused by bacteria.

Pharmacological roles (ChEBI): antibacterial drug, antimicrobial agent.

Also known as: Telavancin, Telavancina, Telavancine, Televancin, telavancin, Telavincin, televancin, TELAVANCIN

Parent form; salt/anhydrous children: CHEMBL3301680

Patent coverage: 1,425 distinct patent families (3,127 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 3,120 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease with sepsis	3	MONDO:0005229	EFO:0003033
bacterial pneumonia	3	MONDO:0004652	EFO:1001272
staphylococcal infection	3	MONDO:0024313	EFO:1001849
bacterial infectious disease	3	MONDO:0005113	EFO:0000771
gram-positive bacterial infections	2	MONDO:0021679	MONDO:0021679
chronic kidney disease	1	MONDO:0005300	EFO:0003884

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 15.

Phase distribution

Phase	Trials
PHASE3	5
PHASE2	4
PHASE4	3
PHASE1	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06119061	PHASE4	RECRUITING	Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular Drainage
NCT02392208	PHASE4	COMPLETED	Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5
NCT03172793	PHASE4	COMPLETED	Telavancin Pharmacokinetics in Cystic Fibrosis Patients
NCT00091819	PHASE3	COMPLETED	Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus
NCT00107952	PHASE3	COMPLETED	Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus
NCT00107978	PHASE3	COMPLETED	Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus
NCT00124020	PHASE3	COMPLETED	Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus
NCT02208063	PHASE3	TERMINATED	A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial
NCT00061633	PHASE2	COMPLETED	Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
NCT00062647	PHASE2	COMPLETED	Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia
NCT00077675	PHASE2	COMPLETED	Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
NCT01321879	PHASE2	COMPLETED	Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients
NCT01238796	PHASE1	COMPLETED	A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin
NCT02013141	PHASE1	TERMINATED	Telavancin Pediatric PK Study (Ages >12 Months to 17 Years)
NCT02753855	PHASE1	COMPLETED	Pharmacokinetics of Telavancin in Normal and Obese Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).